← Swedish Orphan Biovitrum overview

Swedish Orphan Biovitrum vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Swedish Orphan Biovitrum AB (0MTD.LSE)

Q3 2026
▲3▼1

Sobi's profit jumps, guidance raised, and new rare-disease deals expand pipeline

  • FDA rejects gout drug NASP over manufacturing issues The FDA sent a complete response letter for Sobi's gout treatment NASP, asking for more manufacturing data. No clinical safety or efficacy problems were found, but approval is delayed. This pushes the share price down because a near-term launch is now uncertain.

    This is a fresh regulatory setback that delays a potential new product and weighs on the stock.

  • Canada backs EMPAVELI for rare kidney diseases Canada's drug agency gave a positive reimbursement recommendation for EMPAVELI in two rare kidney conditions. This opens a new market for Sobi's drug, which is already approved elsewhere. It lifts the share price by adding a new source of sales growth.

    This is a new market-access win that expands demand for an existing Sobi product.

  • Q2 profit surges and 2026 outlook raised Sobi reported much higher second-quarter profit and revenue, and raised its full-year 2026 guidance for both sales growth and profit margin. This boosts the share price because it shows the core business is performing better than expected and management is more confident.

    This is a new earnings beat and guidance raise that directly improves investor expectations for future profits.

  • Sobi-Innate lacutamab partnership becomes effective Sobi's partnership with Innate Pharma for the cancer drug lacutamab closed, triggering a $75 million payment from Sobi. The deal gives Sobi global commercial rights and a path to accelerated approval. It lifts the share price by adding a late-stage pipeline asset with blockbuster potential.

    This is a new closing of a strategic deal that expands Sobi's pipeline and future revenue prospects.

August 2026
▲3▼1

Sobi's profit jumps, guidance raised, and new rare-disease deals expand pipeline

  • FDA rejects gout drug NASP over manufacturing issues The FDA sent a complete response letter for Sobi's gout treatment NASP, asking for more manufacturing data. No clinical safety or efficacy problems were found, but approval is delayed. This pushes the share price down because a near-term launch is now uncertain.

    This is a fresh regulatory setback that delays a potential new product and weighs on the stock.

  • Canada backs EMPAVELI for rare kidney diseases Canada's drug agency gave a positive reimbursement recommendation for EMPAVELI in two rare kidney conditions. This opens a new market for Sobi's drug, which is already approved elsewhere. It lifts the share price by adding a new source of sales growth.

    This is a new market-access win that expands demand for an existing Sobi product.

  • Q2 profit surges and 2026 outlook raised Sobi reported much higher second-quarter profit and revenue, and raised its full-year 2026 guidance for both sales growth and profit margin. This boosts the share price because it shows the core business is performing better than expected and management is more confident.

    This is a new earnings beat and guidance raise that directly improves investor expectations for future profits.

  • Sobi-Innate lacutamab partnership becomes effective Sobi's partnership with Innate Pharma for the cancer drug lacutamab closed, triggering a $75 million payment from Sobi. The deal gives Sobi global commercial rights and a path to accelerated approval. It lifts the share price by adding a late-stage pipeline asset with blockbuster potential.

    This is a new closing of a strategic deal that expands Sobi's pipeline and future revenue prospects.

Latest
▲3▼1

Sobi's profit jumps, guidance raised, and new rare-disease deals expand pipeline

  • FDA rejects gout drug NASP over manufacturing issues The FDA sent a complete response letter for Sobi's gout treatment NASP, asking for more manufacturing data. No clinical safety or efficacy problems were found, but approval is delayed. This pushes the share price down because a near-term launch is now uncertain.

    This is a fresh regulatory setback that delays a potential new product and weighs on the stock.

  • Canada backs EMPAVELI for rare kidney diseases Canada's drug agency gave a positive reimbursement recommendation for EMPAVELI in two rare kidney conditions. This opens a new market for Sobi's drug, which is already approved elsewhere. It lifts the share price by adding a new source of sales growth.

    This is a new market-access win that expands demand for an existing Sobi product.

  • Q2 profit surges and 2026 outlook raised Sobi reported much higher second-quarter profit and revenue, and raised its full-year 2026 guidance for both sales growth and profit margin. This boosts the share price because it shows the core business is performing better than expected and management is more confident.

    This is a new earnings beat and guidance raise that directly improves investor expectations for future profits.

  • Sobi-Innate lacutamab partnership becomes effective Sobi's partnership with Innate Pharma for the cancer drug lacutamab closed, triggering a $75 million payment from Sobi. The deal gives Sobi global commercial rights and a path to accelerated approval. It lifts the share price by adding a late-stage pipeline asset with blockbuster potential.

    This is a new closing of a strategic deal that expands Sobi's pipeline and future revenue prospects.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 2026
▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

  • Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.

    This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.

  • Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.

    A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.

  • Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.

    Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.

  • US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.

    These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 2026
▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

  • Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.

    This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.

  • Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.

    A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.

  • Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.

    Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.

  • US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.

    These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest
▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

  • Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.

    This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.

  • Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.

    A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.

  • Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.

    Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.

  • US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.

    These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.